NASDAQ: GANX
Gain Therapeutics Inc Stock Ownership - Who owns Gain Therapeutics?

Insider buying vs selling

Have Gain Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when GANX insiders and whales buy or sell their stock.

GANX Shareholders

What type of owners hold Gain Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Khalid Islam2.13%930,784$1.66MInsider
Eric I. Richman0.70%304,458$541.94kInsider
Jeffrey Scott Riley0.07%30,000$53.40kInsider
Matthias Alder0.05%21,140$37.63kInsider
Gene MacK0.03%14,400$25.63kInsider
Salvatore Calabrese0.01%3,000$5.34kInsider
Marwac0.00%1,924$3.42kInstitution
Marshall Wace LLP0.00%1,923$3.42kInstitution
Potomac Capital Management Inc0.00%946$1.68kInstitution
Potom10.00%946$1.68kInstitution

1 of 3

GANX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GANX0.02%2.99%
VRCA0.02%99.98%Net BuyingNet Buying
RNXT0.02%10.44%Net Buying
CING0.01%30.09%Net Buying
KLRS0.01%99.99%Net Buying

Gain Therapeutics Stock Ownership FAQ

Who owns Gain Therapeutics?

Gain Therapeutics (NASDAQ: GANX) is owned by 0.02% institutional shareholders, 2.99% Gain Therapeutics insiders, and 96.99% retail investors. Khalid Islam is the largest individual Gain Therapeutics shareholder, owning 930,784.00 shares representing 2.13% of the company. Khalid Islam's Gain Therapeutics shares are currently valued at $1.64M.

If you're new to stock investing, here's how to buy Gain Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.